Zhao, Wei
Ma, Bo
Tian, Zhihua
Han, Haibo
Tang, Jintian
Dong, Bin
An, Guo
Cao, Baoshan
Wang, Boqing
Funding for this research was provided by:
National Natural Science Foundation of China (81872025)
Article History
Received: 18 February 2020
Revised: 7 December 2020
Accepted: 10 December 2020
First Online: 21 January 2021
Ethics approval and consent to participate
: The human HCC cell lines PLC (catalogue number: CRL-8024™) was obtained from the Global Bioresource Center of American Type Culture Collection (ATCC) and Huh7 (catalogue number: JCRB0403) was purchased from Health Science Research Resources Bank (Osaka, Japan). All mouse experiments were carried out in PUCH (license number: SYXK 2016-0015) and conformed to the regulatory standards of PUCH on Laboratory Animals Care (EAEC 2018-14) and Use in accordance with the National Institutes of Health Guide (Guide for the Care and Use of Laboratory Animals, 2011). This study was performed in accordance with the Declaration of Helsinki. Mice were sacrificed by CO<sub>2</sub> rapidly without suffering. The acquisition and use of patient tissues were permitted based on the acquisition of informed consent according to the protocol approved by the Ethics Committee of Affiliated Tumor Hospital of Xinjiang Medical University (no. G-201419).
: All original data are archived and stored at the PUCH, Beijing, China. The cell lines generated in this study and controls will be made available to other researchers upon request, including Huh7 and PLC sorafenib-resistant cell lines.
: The authors declare no competing interests.
: This study was funded by the National Natural Science Foundation of China (81872025, 81460360, and 81772632), the Beijing Natural Science Foundation (7182030), the Clinical Features Research of Capital (No. Z151100004015173), Natural Science Foundation of Xinjiang Uygur Autonomous Region (2015211C126) and the grant from Scientific Research Foundation for Returned Scholars, Peking University Third Hospital (No. Y76476-05).